Corvus Pharmaceuticals, Inc. (CRVS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $670.56M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $667.78M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $474.39M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $472.79M; Additional Paid in CapitalUSD (m).
Corvus Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.00K | (m) | $670.56M | $-1.29M | $-443.94M | $225.33M | 3 month · $2.61M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $8.00K | (m) | $667.78M | $-1.13M | $-425.99M | $240.68M | 3 month · $2.65M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $7.00K | (m) | $474.39M | $-896.00K | $-412.29M | $61.20M | 12 month · $5.33M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $7.00K | $472.79M | (m) | $-1.06M | $-399.97M | $71.77M | 3 month · $1.25M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $7.00K | $471.18M | (m) | $-1.15M | $-389.81M | $80.23M | 3 month · $1.26M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.00K | $432.39M | (m) | $-1.25M | $-381.82M | $49.33M | 3 month · $1.25M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $7.00K | $430.86M | $430.86M | $-1.29M | $-397.01M | $32.57M | 12 month · $3.00M | 12 month · $5.03M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.00K | $398.04M | (m) | $-738.00K | $-384.90M | $12.41M | 3 month · $733.00K | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $6.00K | $397.25M | (m) | $-1.35M | $-344.68M | $51.23M | 3 month · $768.00K | 3 month · $5.03M | (m) | (m) | (m) |
| 2024-05-06 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $5.00M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $5.00K | $375.05M | (m) | $-1.27M | $-340.42M | $33.36M | 3 month · $689.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $5.00K | $374.36M | (m) | $-967.00K | $-334.72M | $38.68M | 12 month · $2.15M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $5.00K | $373.79M | (m) | $-1.44M | $-328.06M | $44.29M | 3 month · $546.00K | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.00K | $372.91M | (m) | $-1.37M | $-322.06M | $49.48M | 3 month · $537.00K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $5.00K | $364.86M | (m) | $-434.00K | $-315.56M | $48.87M | 3 month · $492.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.00K | $364.36M | (m) | $-563.00K | $-307.69M | $56.12M | 12 month · $2.69M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $5.00K | $363.74M | (m) | $-1.19M | $-297.87M | $64.68M | 3 month · $658.00K | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.00K | $363.08M | (m) | $339.00K | $-283.04M | $80.39M | 3 month · $675.00K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.00K | $362.41M | (m) | $1.99M | $-274.68M | $89.72M | 3 month · $739.00K | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $5.00K | $361.67M | (m) | $1.87M | $-266.38M | $97.16M | 12 month · $4.23M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $5.00K | $360.91M | (m) | $1.38M | $-257.14M | $105.15M | 3 month · $1.10M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.00K | $341.48M | (m) | $1.40M | $-246.47M | $96.40M | 3 month · $1.17M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.00K | $329.10M | (m) | $6.00K | $-234.72M | $94.39M | 3 month · $1.23M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.00K | $295.28M | (m) | $4.00K | $-223.14M | $72.15M | 12 month · $5.75M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $3.00K | $292.82M | (m) | $12.00K | $-250.49M | $42.35M | 3 month · $1.28M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $3.00K | $291.48M | (m) | $53.00K | $-240.69M | $50.84M | 3 month · $1.38M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.00K | $290.07M | (m) | $43.00K | $-230.08M | $60.03M | 3 month · $1.84M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.00K | $288.22M | (m) | $29.00K | $-217.15M | $71.11M | 12 month · $7.35M | (m) | (m) | (m) | 12 month · $12.00K |
| 2019-09-30 | (m) | $3.00K | $286.47M | (m) | $34.00K | $-206.10M | $80.41M | 3 month · $1.75M | (m) | (m) | (m) | 3 month · $3.00K |
| 2019-06-30 | (m) | $3.00K | $284.71M | (m) | $39.00K | $-195.09M | $89.65M | 3 month · $1.90M | (m) | (m) | (m) | 3 month · $4.00K |
| 2019-03-31 | (m) | $3.00K | $282.80M | (m) | $11.00K | $-182.12M | $100.70M | 3 month · $1.95M | (m) | (m) | (m) | 3 month · $5.00K |
| 2018-12-31 | (m) | $3.00K | $280.84M | (m) | $-34.00K | $-170.47M | $110.34M | 12 month · $7.13M | (m) | (m) | (m) | 12 month · $28.00K |
| 2018-09-30 | (m) | $3.00K | $278.84M | (m) | $-35.00K | $-159.96M | $118.85M | 3 month · $1.79M | (m) | (m) | (m) | 3 month · $7.00K |
| 2018-06-30 | (m) | $3.00K | $276.88M | (m) | $-20.00K | $-149.47M | $127.40M | 3 month · $1.74M | (m) | (m) | (m) | 3 month · $6.00K |
| 2018-03-31 | (m) | $3.00K | $275.10M | (m) | $-39.00K | $-137.84M | $137.23M | 3 month · $1.80M | (m) | (m) | (m) | 3 month · $7.00K |
| 2017-12-31 | (m) | $2.00K | $208.41M | (m) | $-41.00K | $-123.53M | $84.83M | 12 month · $6.23M | (m) | (m) | (m) | 12 month · $28.00K |
| 2017-09-30 | (m) | $2.00K | $205.35M | (m) | $-14.00K | $-111.61M | $93.74M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $2.00K | $203.72M | (m) | $-52.00K | $-98.89M | $104.78M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.00K | $202.19M | (m) | $-62.00K | $-83.91M | $118.22M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.00K | $200.71M | (m) | $-39.00K | $-67.87M | $132.80M | 12 month · $3.83M | (m) | (m) | 12 month · $7.41M | 12 month · $34.00K |
| 2016-09-30 | (m) | $2.00K | $199.65M | (m) | $41.00K | $-56.78M | $142.91M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $2.00K | $198.38M | (m) | $78.00K | $-46.49M | $151.97M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.00K | $190.36M | (m) | $29.00K | $-37.84M | $152.55M | (m) | (m) | $74.00K | (m) | (m) |
| 2015-12-31 | (m) | (m) | $440.00K | (m) | $-45.00K | $-31.50M | $-31.10M | 12 month · $428.00K | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $-159.00K | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |